NCT04238715 2026-03-02
A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
Eisai Inc.
Phase 2 Completed
Clinical Trials
5 trialsNCT02924376 2025-08-14
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
Incyte Corporation
Phase 2 Completed
NCT02699606 2025-04-27
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma
Janssen Research & Development, LLC
Phase 2 Completed
NCT05019794 2022-06-27
FGFR
LianBio LLC
Phase 2 Unknown
NCT01367275 2020-09-03
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
M.D. Anderson Cancer Center
Phase 2 Terminated